P833 Burden of steroid use in patients with moderate ulcerative colitis in Europe and the United States

S Shah,H Knight,G O’Neill,R Lukanova,K Davé,M Rosen

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0963

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Steroids are an effective short-term therapy option for induction of remission of ulcerative colitis (UC). However, long-term and frequent steroid use is common in clinical practice despite the risks of complications and adverse events.1 We aimed to describe disease burden in moderate UC patients (pts) based on their steroid use history. Methods Data were drawn from the Adelphi UC Disease Specific ProgrammeTM, a cross-sectional survey of gastroenterologists (GIs) and their pts in France, Germany, Italy, Spain, the UK and US from Jan 2020–Mar 2021. GIs reported patient demographics, clinical characteristics, treatments and healthcare resource utilization (HCRU). Pts reported quality of life (QoL) via the EQ-5D, short inflammatory bowel disease questionnaire (SIBDQ), and work productivity and activity impairment (WPAI) questionnaire. Pts had received 5-ASA or immunomodulator with no biologic or Janus kinase inhibitor in the 90 days following treatment initiation, had a history of physician-assessed moderate disease severity or a Mayo endoscopic subscore of 2, and no history of colectomy. Pts were categorized as: no steroids (NS; never received steroids), short term/intermittent (ST/I; currently receiving intermittent steroids or received steroids within the last two years for <90 days), or long term/escalated (LT/E; received steroids for ≥90 days within the last two years or had undergone steroid dose escalation within their current course). Analyses were descriptive. Results Overall, 217NS, 88 ST/I and 172 LT/E pts were analysed (Table 1). Median (interquartile range) total steroid use duration was 4.1 (1.6–22.3) months for ST/I and 14.9 (5.8–36.7) months for LT/E. NS (24.4%), ST/I (25.0%) and LT/E (26.2%) pts experienced abdominal pain; 0.5%, 4.6% and 5.2% had severe/extremely severe pain, respectively. Non-bloody diarrhoea was reported by 16.6%, 14.8%, 20.9% of pts, respectively. In the last 12 months, mean (standard deviation; SD) number of health care visits for NS, ST/I and LT/E was 6.1 (6.2), 7.3 (4.8), 8.0 (7.1); mean (SD) number of tests was 20.8 (17.2), 23.3 (15.7), 25.2 (18.2), respectively. NS, ST/I and LT/E patients reported mean EQ-5D scores (0.85, 0.81, 0.79), SIBDQ total scores (54.6, 49.7, 48.3) and overall work impairment (19.4, 23.1, 27.7). Key comorbidities experienced by ST/I and LT/E were hypertension, depression and diabetes (Figure 1). Conclusion Patients with long-term or escalated steroid use had high symptom burden, frequent comorbidities, high HCRU, and poor QoL. This highlights the need for alternative treatment approaches for moderate UC patients to avoid long-term steroid use. 1. Cross R.K. Inflamm Bowel Dis. 2017;23(10):1689–1701

gastroenterology & hepatology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: **Describe the disease burden of patients with moderate ulcerative colitis (UC) according to their glucocorticoid use history**.

Specifically, the study aims to explore the following aspects:

1. **The current situation of glucocorticoid use and its impact on patients**:
- Glucocorticoids are an effective short - term treatment option for inducing remission in patients with moderate ulcerative colitis. However, in clinical practice, long - term and frequent use of glucocorticoids is common, despite the risk of complications and adverse events.

2. **The impact of different glucocorticoid use patterns on patients' health and quality of life**:
- The study divided patients into three groups: never - used glucocorticoids (NS), short - term / intermittent use (ST/I), and long - term / escalated use (LT/E). By comparing the differences in symptoms, comorbidities, healthcare resource utilization (HCRU), and quality of life (QoL) among these three groups of patients, the specific impact of glucocorticoid use on patients was evaluated.

3. **The necessity of finding alternative treatment options**:
- By analyzing the high symptom burden, frequent comorbidities, high healthcare resource utilization, and poor quality of life in patients with long - term or escalated use of glucocorticoids, the importance of finding alternative treatment options for patients with moderate ulcerative colitis was emphasized to avoid the risks associated with long - term use of glucocorticoids.

### Main Conclusions
The study shows that patients with long - term or escalated use of glucocorticoids have a higher symptom burden, frequent comorbidities, high healthcare resource utilization, and poor quality of life. This highlights the urgent need to find alternative treatment options for patients with moderate ulcerative colitis to reduce the risks of long - term use of glucocorticoids.

### Method Overview
- **Data Source**: Adelphi UC Disease Specific Programme™, a cross - sectional survey covering gastroenterologists and their patients in France, Germany, Italy, Spain, the United Kingdom, and the United States.
- **Patient Classification**: Divided into three groups (NS, ST/I, LT/E) according to glucocorticoid use history.
- **Analysis Content**: Including patients' demographic characteristics, clinical characteristics, treatment status, healthcare resource utilization, quality of life scores, etc.

Through these analyses, the study reveals the specific impact of glucocorticoid use on patients with moderate ulcerative colitis and provides an important basis for future treatment strategies.